Company intelligence / Profile preview

Beijing Darwin Cell Biotechnology Co., Ltd.

Ownership: Private
Development stage: Phase 1

Overview

The company has achieved breakthrough results in clinical experiments on nerve repair using protein assemblies. Their lead program 'Alitol' has shown promising efficacy and safety. A double-blind clinical trial ('IIT') was initiated in acromegaly at Beijing Tiantan Hospital in late-2023. Some COVID-19 related programs with HUMSCs/exosomes were suspended.[1][2][3]

Therapeutic areas: EndocrinologyRheumatologyNeurology
Modalities: Stem cellsExosomes"ECIWEP" protein polymer extraction technology
Industry: Biotech

Drug pipeline

2 assets

ECIWEP

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Beijing Darwin Cell Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Darwin Cell Biotechnology Co., Ltd..

Explore the full profile